Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe Sells 2,500 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $47.10, for a total value of $117,750.00. Following the completion of the sale, the senior vice president now directly owns 2,426 shares of the company’s stock, valued at approximately $114,264.60. This represents a 50.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Mirum Pharmaceuticals Stock Down 3.8 %

Shares of NASDAQ MIRM opened at $44.50 on Friday. The stock has a fifty day moving average price of $40.12 and a 200 day moving average price of $36.00. The company has a current ratio of 3.34, a quick ratio of 3.09 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.14 and a 12-month high of $48.89. The company has a market cap of $2.14 billion, a P/E ratio of -22.03 and a beta of 1.16.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. The business had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company’s revenue for the quarter was up 89.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.57) earnings per share. Research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.81 EPS for the current fiscal year.

Analysts Set New Price Targets

MIRM has been the subject of several recent analyst reports. Evercore ISI lifted their price target on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Cantor Fitzgerald upped their price target on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, August 8th. Citigroup lifted their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday. HC Wainwright reissued a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday. Finally, Robert W. Baird increased their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday. Ten research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $57.73.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after purchasing an additional 318 shares in the last quarter. Amalgamated Bank grew its stake in shares of Mirum Pharmaceuticals by 60.8% during the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after acquiring an additional 513 shares in the last quarter. Arizona State Retirement System increased its position in shares of Mirum Pharmaceuticals by 10.6% during the second quarter. Arizona State Retirement System now owns 9,210 shares of the company’s stock worth $315,000 after acquiring an additional 883 shares during the last quarter. Quest Partners LLC lifted its stake in shares of Mirum Pharmaceuticals by 7,513.3% in the second quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock worth $39,000 after acquiring an additional 1,127 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in Mirum Pharmaceuticals by 11.7% in the first quarter. Russell Investments Group Ltd. now owns 17,481 shares of the company’s stock valued at $439,000 after purchasing an additional 1,825 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.